About La Jolla Pharmaceutical Company (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Industry, Sector and Symbol:
- Market Cap: $750.63 million
- Outstanding Shares: 22,123,000
- 50 Day Moving Avg: $34.15
- 200 Day Moving Avg: $30.90
- 52 Week Range: $14.63 - $39.28
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.55
- P/E Growth: -0.53
- Annual Revenue: $128,999.00
- Price / Sales: 5,818.91
- Book Value: $6.04 per share
- Price / Book: 5.62
- EBITDA: ($95,320,000.00)
- Return on Equity: -91.66%
- Return on Assets: -80.61%
- Current Ratio: 17.41%
- Quick Ratio: 17.41%
- Average Volume: 270,814 shs.
- Beta: 1.74
- Short Ratio: 23.18
Frequently Asked Questions for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
What is La Jolla Pharmaceutical Company's stock symbol?
La Jolla Pharmaceutical Company trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical Company's earnings last quarter?
La Jolla Pharmaceutical Company (NASDAQ:LJPC) issued its quarterly earnings data on Thursday, July, 27th. The company reported ($1.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.13) by $0.09. During the same period in the previous year, the company posted ($0.90) earnings per share. View La Jolla Pharmaceutical Company's Earnings History.
When will La Jolla Pharmaceutical Company make its next earnings announcement?
Where is La Jolla Pharmaceutical Company's stock going? Where will La Jolla Pharmaceutical Company's stock price be in 2017?
6 analysts have issued 12 month target prices for La Jolla Pharmaceutical Company's shares. Their forecasts range from $36.00 to $85.00. On average, they anticipate La Jolla Pharmaceutical Company's share price to reach $54.60 in the next year. View Analyst Ratings for La Jolla Pharmaceutical Company.
What are analysts saying about La Jolla Pharmaceutical Company stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical Company stock:
- 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (10/17/2017)
- 2. Cowen and Company analysts commented, "LJPC reported Q1 financials." (4/28/2017)
- 3. Chardan Capital analysts commented, "We believe the results are compelling and, based on the SPA, will likely result in LJPC-501 US approval. Recall from our 24 January 2017 note where we discussed the SPA, stating with regards to the primary endpoint," (3/2/2017)
- 4. SunTrust Banks, Inc. analysts commented, "strong" ATHOS-3 data which implies LJPC-501 could be standard-of-care in last-line CRH.Suneja commented, "We believe today's highly favorable ATHOS-3 data (primary endpoint met; positive trend in mortality) are supportive of approval in CRH, which could be at least $500MM opportunity; an NDA filing is expected in 2H17 and full data are expected in 2017 at a major medical conference and publication in a "top-tier" journal. In our view, these results provide validation for LJPC's capital-efficient strategy of developing naturally occurring peptides with well-understood biological functions for life-threatening diseases. We reiterate our Buy rating and increase our NPV-derived PT to $57 from $38." (2/27/2017)
Who are some of La Jolla Pharmaceutical Company's key competitors?
Some companies that are related to La Jolla Pharmaceutical Company include Acceleron Pharma (XLRN), AnaptysBio (ANAB), Clinigen Group PLC (CLIN), Five Prime Therapeutics (FPRX), Acorda Therapeutics (ACOR), Ascendis Pharma A/S (ASND), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), NeuroDerm (NDRM), Athenex (ATNX), Epizyme (EPZM), Xencor (XNCR), REGENXBIO (RGNX), Retrophin (RTRX) and Amarin Corporation PLC (AMRN).
Who are La Jolla Pharmaceutical Company's key executives?
La Jolla Pharmaceutical Company's management team includes the folowing people:
- Kevin C. Tang, Chairman of the Board
- George F. Tidmarsh M.D. Ph.D., President, Chief Executive Officer, Secretary, Director
- Dennis M. Mulroy CPA, Chief Financial Officer
- Jennifer A. Carver, Senior Vice President,Operations
- Lakhmir S. Chawla M.D., Chief Medical Officer
- Laura Douglass, Independent Director
- Craig A. Johnson, Independent Director
- Robert Harvey Rosen, Independent Director
How do I buy La Jolla Pharmaceutical Company stock?
Shares of La Jolla Pharmaceutical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical Company's stock price today?
MarketBeat Community Rating for La Jolla Pharmaceutical Company (NASDAQ LJPC)MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of La Jolla Pharmaceutical Company stock can currently be purchased for approximately $33.93.
Consensus Ratings for La Jolla Pharmaceutical Company (NASDAQ:LJPC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$54.60 (60.92% upside)|Consensus Price Target History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Analysts' Ratings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/3/2017||Jefferies Group LLC||Reiterated Rating||Buy||$40.00||Low|
|8/30/2017||J P Morgan Chase & Co||Initiated Coverage||Overweight -> Overweight||$36.00||Low|
|8/8/2017||Chardan Capital||Reiterated Rating||Buy||$85.00||Low|
|5/22/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$57.00||Medium|
|4/30/2017||Noble Financial||Reiterated Rating||Buy||Low|
|4/28/2017||Cowen and Company||Reiterated Rating||Buy||$55.00||Low|
|5/24/2016||Lake Street Capital||Initiated Coverage||Buy||$25.00||N/A|
Earnings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)Earnings History by Quarter for La Jolla Pharmaceutical Company (NASDAQ LJPC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017|| || || || || || || || |
|7/27/2017||Q2 2017||($1.13)||($1.21)||$0.03 million||View||N/A|
|4/27/2017||Q1 2017||($1.34)||($1.26)||$0.17 million||View||N/A|
|2/23/2017||Q4 2016||($1.20)||($1.44)||$0.16 million||$0.09 million||View||N/A|
|11/3/2016||Q3||($0.97)||($1.23)||$0.26 million||$0.04 million||View||N/A|
|8/8/2016||Q2||($0.99)||($0.90)||$0.25 million||$0.25 million||View||N/A|
|5/6/2016||Q416||($0.74)||($0.96)||$0.43 million||$0.23 million||View||N/A|
Earnings Estimates for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
2017 EPS Consensus Estimate: ($4.89)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Insider Ownership Percentage: 25.47%Insider Trades by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/23/2017||Kevin C Tang||Director||Buy||149,254||$33.50||$5,000,009.00|| |
|3/3/2017||Dennis Mulroy||CFO||Buy||500||$33.95||$16,975.00|| |
|3/3/2017||George F Tidmarsh||CEO||Buy||3,000||$34.17||$102,510.00|| |
|3/3/2017||Lakhmir S Chawla||Insider||Buy||1,600||$34.80||$55,680.00|| |
|9/13/2016||Kevin C Tang||Director||Buy||139,035||$19.82||$2,755,673.70|| |
|3/4/2016||Kevin C Tang||Director||Buy||20,000||$19.85||$397,000.00|| |
|3/1/2016||George F Tidmarsh||CEO||Buy||2,000||$16.57||$33,140.00|| |
|9/28/2015||Lakhmir S Chawla||Insider||Buy||485||$27.75||$13,458.75|| |
|9/10/2015||Kevin C Tang||Director||Buy||80,000||$38.00||$3,040,000.00|| |
|8/21/2015||Kevin C Tang||Director||Buy||170,000||$27.11||$4,608,700.00|| |
|6/26/2015||Kevin C Tang||Director||Buy||110,000||$23.58||$2,593,800.00|| |
|6/24/2015||Kevin C Tang||Director||Buy||220,000||$22.23||$4,890,600.00|| |
|6/23/2015||Kevin C Tang||Director||Buy||53,836||$22.27||$1,198,927.72|| |
|6/22/2015||Kevin C Tang||Director||Buy||77,850||$21.41||$1,666,768.50|| |
|5/13/2015||Kevin C Tang||Director||Buy||190,583||$18.24||$3,476,233.92|| |
|5/12/2015||George F Tidmarsh||CEO||Buy||4,000||$18.37||$73,480.00|| |
|12/15/2014||Kevin C Tang||Director||Buy||232,343||$12.84||$2,983,284.12|| |
|12/11/2014||George F Tidmarsh||CEO||Buy||4,000||$11.38||$45,520.00|| |
|9/26/2014||George F Tidmarsh||CEO||Buy||2,000||$9.35||$18,700.00|| |
|9/26/2014||Kevin C Tang||Director||Buy||169,555||$9.14||$1,549,732.70|| |
|9/25/2014||Kevin C Tang||Director||Buy||30,500||$9.17||$279,685.00|| |
|9/24/2014||Kevin C Tang||Director||Buy||95,000||$9.10||$864,500.00|| |
|9/18/2014||George F Tidmarsh||CEO||Buy||5,000||$9.18||$45,900.00|| |
|7/23/2014||George F Tidmarsh||CEO||Buy||19,000||$10.50||$199,500.00|| |
|5/21/2014||George Tidmarsh||CEO||Buy||12,000||$7.37||$88,440.00|| |
|4/14/2014||George Tidmarsh||CEO||Buy||8,000||$9.53||$76,240.00|| |
|2/7/2014||George F Tidmarsh||CEO||Buy||3,000||$7.25||$21,750.00|| |
Headline Trends for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Latest Headlines for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Loading headlines, please wait.
La Jolla Pharmaceutical Company (LJPC) Chart for Monday, October, 23, 2017